Great post and exactly how I feel about the PR and the path forward. IMO, the use of “significant” in this PR refers to the reduction in the CTC levels from baseline and not a reference to the data significance. The question is how significant? 30%? 50%? 75%? I’m sure even a 30% reduction would be big news as Leronlimab could be combined with other treatment to extend life and eliminate cancer. Only time will tell, but I believe the trial Enrollment will go faster and by Spring we should hopefully have enough data to say definitively how well leronlimab works against mTNBC.